Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Clinical trial NCT04013672 · COMPLETED

Trial details

NCT number: NCT04013672
Sponsor: David Peereboom
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Recurrent Glioblastoma

Start date: 2020-03-19
Primary completion: 2021-08-16
Enrollment: 41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.